Steph & Co. Acquires 55 Shares of ICON Public Limited (NASDAQ:ICLR)

Steph & Co. lifted its holdings in ICON Public Limited (NASDAQ:ICLR) by 3.7% in the fourth quarter, HoldingsChannel.com reports. The fund owned 1,560 shares of the medical research company’s stock after buying an additional 55 shares during the quarter. Steph & Co.’s holdings in ICON Public were worth $327,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in ICLR. GAMMA Investing LLC grew its stake in ICON Public by 64.0% during the fourth quarter. GAMMA Investing LLC now owns 433 shares of the medical research company’s stock valued at $91,000 after acquiring an additional 169 shares in the last quarter. Foyston Gordon & Payne Inc purchased a new position in shares of ICON Public during the third quarter valued at about $11,672,000. Icon Wealth Advisors LLC lifted its position in shares of ICON Public by 861.1% in the third quarter. Icon Wealth Advisors LLC now owns 13,215 shares of the medical research company’s stock worth $3,797,000 after buying an additional 11,840 shares in the last quarter. First Horizon Advisors Inc. grew its holdings in ICON Public by 33.9% during the 3rd quarter. First Horizon Advisors Inc. now owns 597 shares of the medical research company’s stock valued at $172,000 after buying an additional 151 shares in the last quarter. Finally, Arkadios Wealth Advisors increased its stake in ICON Public by 5.0% in the 3rd quarter. Arkadios Wealth Advisors now owns 1,293 shares of the medical research company’s stock worth $371,000 after acquiring an additional 62 shares during the last quarter. Hedge funds and other institutional investors own 95.61% of the company’s stock.

ICON Public Stock Down 0.4 %

NASDAQ:ICLR opened at $199.47 on Thursday. The company has a market cap of $16.46 billion, a price-to-earnings ratio of 22.24, a price-to-earnings-growth ratio of 1.59 and a beta of 1.20. ICON Public Limited has a twelve month low of $183.38 and a twelve month high of $347.72. The stock has a fifty day simple moving average of $210.30 and a 200-day simple moving average of $269.51. The company has a current ratio of 1.34, a quick ratio of 1.34 and a debt-to-equity ratio of 0.35.

ICON Public (NASDAQ:ICLR) last issued its earnings results on Wednesday, October 23rd. The medical research company reported $3.35 EPS for the quarter, missing analysts’ consensus estimates of $3.72 by ($0.37). ICON Public had a return on equity of 11.91% and a net margin of 9.00%. The company had revenue of $2.03 billion during the quarter, compared to the consensus estimate of $2.13 billion. During the same quarter in the prior year, the company earned $3.10 earnings per share. ICON Public’s revenue was down 1.2% on a year-over-year basis. Analysts anticipate that ICON Public Limited will post 13.41 EPS for the current year.

Analyst Ratings Changes

A number of research analysts recently weighed in on ICLR shares. Redburn Atlantic started coverage on shares of ICON Public in a report on Monday, October 14th. They issued a “neutral” rating and a $311.00 target price for the company. StockNews.com cut shares of ICON Public from a “buy” rating to a “hold” rating in a research note on Thursday, September 19th. Leerink Partnrs upgraded shares of ICON Public to a “strong-buy” rating in a research report on Wednesday, September 18th. Leerink Partners reiterated an “outperform” rating and issued a $255.00 price target (down previously from $270.00) on shares of ICON Public in a research report on Tuesday, November 19th. Finally, Evercore ISI decreased their price objective on ICON Public from $360.00 to $350.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. Four analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $287.00.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.